You are here:

AOP Orphan Contact

AOP Orphan worldwide

Wilhelminenstraße 91/IIf
1160 Vienna, Austria

Current studies

Focus: Myeloproliferative diseases/neoplasms

Indication: essential thrombocythemia 
Name of Study: ARETA

  • Essential thrombocythemia indication: Name of Study ARETA Anagrelide Retard vs. Placebo: Efficacy and safety in “at-risk” patients with essential thrombocythemia (ARETA).
  • The study consists of a multicenter, phase III , randomized, subject and sponsor-blinded, placebo-controlled study to determine the effect of “anagrelide retard” on subjects with essential thrombocythemia (ET) at “defined risk.”

  • Link to the ARETA study on

Indication: polycythemia vera
Name of study: PEGINVERA

  • Safety study of pegylated interferon alpha 2b to treat polycythemia vera (PEGINVERA).
  • The goal of this study is to identify the maximum tolerated dose (MTD) of the medication under investigation. Moreover, the safety and tolerability will be assessed and an exploratory analysis of efficacy and biomaker modulation will be performed.

  • Link to the PEGINVERA study on

Indication: polyzythämia vera
Name of study: PROUD-PV

  • Pegylated interferon alpha-2b versus hydroxyurea in polycythemia vera
  • The PROUD-PV study is a phase III study to compare the efficacy and safety of the novel monopegylated interferon alpha 2b AOP2014 versus hydroxyurea (the current licensed therapy for this disease) in both HU naive and currently treated patients, diagnosed with polycythemia vera.

  • PROUD-PV study website
  • Link to the PROUD-PV study on

Focus: Cardiology

A short term pharmacokinetic, pharmacodynamic and tolerability study to compare AOP200704 vs. esmolol.